Evaluating the Safety and Rationale for Cinacalcet Posttransplant Hyperparathyroidism and Hypercalcemia.

unboundmedicine.com Evaluating the Safety and Rationale for Cinacalcet Posttransplant Hyperparathyroidism and Hypercalcemia.

Unbound MEDLINE

Links

Publisher Full Text

Authors

Coyne DW, Santos RD

Source

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons : 2014 Sep 15 pg

Pub Type(s)

EDITORIAL

Language

ENG

PubMed ID

25223316

Related Citations

• Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
• Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.
• Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis.
• Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism.
• Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation.
• Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.
• Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride.
• Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.

More

http://www.unboundmedicine.com/medline/citation/25223316/Evaluating_the_Safety_and_Rationale_for_Cinacalcet_Posttransplant_Hyperparathyroidism_and_Hypercalcemia_

Sent with Reeder

Alberto Reino Buelvas